Xenon Pharmaceuticals (XENE) voluntarily halted enrollment in a handful of studies Friday due to several unexpected side effects. The biotech stock crashed to a six-month low. The drug at the center of the debacle is azetukalner, which Xenon is hoping will soon gain approval to treat epilepsy. Xenon stock shot 50% higher on March 9 following positive results for azetukalner…
The Biotech Surged 50% On Positive Data In March. Now, It's Almost Gone.
Kaynak: Yahoo Finance
İlgili Haberler
Global
Putin says EU is losing industry, falling behind competition ahead of meeting with Trump, Xi
CNBC Finance · 8 dk önce
Global
"Breaking Bad" dizisinin yıldızı Dean Norris, boşanma sürecindeyken 4,5 hektarlık Kaliforniya'daki mülkünü 3,2 milyon dolara satıyor
MarketWatch Top · 18 saat önce
Global
Nvidia'dan Apple'a kadar ABD'li şirketler artan bir Çin ikilemiyle karşı karşıya
CNBC Finance · 19 saat önce
Global
Berkshire Hathaway raised its stake in Delta in the third quarter. It also trimmed a key bank holding
CNBC Finance · 1 gün önce
Global
JPMorgan Chase says temporary software bug is affecting consumer banking
CNBC Finance · 1 gün önce
Yorumlar (0)
Giriş yaparak yorum yazabilirsin.
İlk yorumu sen yaz.